{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:35:43Z","timestamp":1788521743800,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T00:00:00Z","timestamp":1276819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:styled-content>Purpose:<\/jats:styled-content>\u2002<\/jats:bold>Monotherapy approvals have been difficult to obtain from the U.S. Food and Drug Administration (FDA), and have almost all been achieved using a trial design entitled \u201cwithdrawal to monotherapy\u201d in treatment\u2010resistant patients, which employs a so\u2010called \u201cpseudo\u2010placebo\u201d as a comparator arm. The authors submitted a white paper to the FDA advocating use of a virtual placebo historical control as an alternative to pseudo\u2010placebo. Such an approach reduces patient risk that would result from exposure to pseudo\u2010placebo. In this article, we present the data submitted to the FDA to justify a historical control.<\/jats:p><jats:p><jats:bold><jats:styled-content>Methods:<\/jats:styled-content>\u2002<\/jats:bold>We analyzed individual patient data from eight previously completed withdrawal to monotherapy studies, which we determined had similar design. All studies employed percent meeting predetermined exit criteria (denoting worsening of seizure control) as the outcome measure. Kaplan\u2010Meier estimates of the percent exiting were calculated at 112\u2003days.<\/jats:p><jats:p><jats:bold><jats:styled-content>Results:<\/jats:styled-content>\u2002<\/jats:bold>The percent meeting exit criteria were uniformly high, ranging from 74.9\u201395.9%. The eight studies appear to meet the criteria set forth for use of historical control. The estimate of the combined percent exit based on the noniterative mixed\u2010effects model is 85.1%, with a lower bound of the 95% prediction interval of 65.3%, and 72.2% for an 80% prediction interval.<\/jats:p><jats:p><jats:bold><jats:styled-content>Conclusion:<\/jats:styled-content>\u2002<\/jats:bold>There is justification for proposing that these data can serve as a historical control for future monotherapy studies, obviating the need for a placebo\/pseudo\u2010placebo arm in trials intended to demonstrate the efficacy of approved drugs as monotherapy in treatment\u2010resistant patients.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2010.02650.x","type":"journal-article","created":{"date-parts":[[2010,6,18]],"date-time":"2010-06-18T15:51:49Z","timestamp":1276876309000},"page":"1936-1943","source":"Crossref","is-referenced-by-count":73,"title":["Historical control monotherapy design in the treatment of epilepsy"],"prefix":"10.1111","volume":"51","author":[{"given":"Jacqueline A.","family":"French","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Temkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2307\/2685469"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.3.746"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.12.2245"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox D","year":"1972","journal-title":"J R Stat Soc B"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.4.688"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.1018"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2005.09.034"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1991.tb04715.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320313"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01120.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.5.864"},{"key":"e_1_2_8_16_1","unstructured":"SepracorInc. (2009)Safety and efficacy of eslicarbazepine acetate monotherapy in subjects with partial epilepsy not well controlled by current antiepileptic drugs. NCT trial Number NCT00866775."},{"key":"e_1_2_8_17_1","unstructured":"UCB Inc. (2009a)Conversion to monotherapy study with Keppra XR for partial seizures. NCT trial Number NCT00419094."},{"key":"e_1_2_8_18_1","unstructured":"UCB Inc. (2009b)A double\u2010blind randomized conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (\u226516 to 75 Years Old) with partial onset seizures. NCT Trial Number NCT00698581."},{"key":"e_1_2_8_19_1","unstructured":"UCB Inc. (2009c)A double\u2010blind randomized conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (\u226516 to 75 Years Old) with partial onset seizures. NCT Trial Number NCT00699283."},{"key":"e_1_2_8_20_1","unstructured":"UCB Inc. (2009d)Trial to demonstrate the efficacy and safety of conversion to lacosamide monotherapy for partial\u2010onset seizures (ALEX\u2010MT). NCT Trial Number NCT00520741."}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2010.02650.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2010.02650.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T02:36:41Z","timestamp":1740191801000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2010.02650.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,18]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1528-1167.2010.02650.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02650.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,18]]}}}